

To Financial Editors:
【For Immediate Release】



聯邦制藥國際控股有限公司
The United Laboratories International Holdings Limited
(SEHK: 03933)

Remarkable Results for Supportive Long-term Stakeholders
Product Innovation for Continuous Long-term Growth

Financial Highlights of 2010 Annual Results

	As of 31 December (HK\$m)		
	2010	2009	Change
Turnover	6,502.8	4,643.2	+40.1%
Gross profit	2,568.1	1,814.0	+41.6%
EBITDA	1,674.2	1,120.4	+49.4%
Profit attributable to shareholders	974.2	541.4	+79.9%
Earnings per share (HK cents)	78.2	45.1	+73.4%
Dividend (HK cents)	30.0*	19.0	+57.9%

*Final dividend: HK18 cents

【22 March 2011 - Hong Kong】 - The United Laboratories International Holdings Limited (“TUL” or the “Group”; Stock code: 3933), one of the leading manufacturers of antibiotics in the PRC, announced today its annual results for the year ended 31 December 2010.

The Group’s turnover grew by 40.1% to a new record of HK\$6.50 billion in 2010 (2009: HK\$4.64 billion). The Group’s profit attributable to shareholders, that showed a 79.9% growth to HK\$974 million (2009: HK\$541 million), broke the record high as well. The board proposed a final dividend of HK18 cents per share. The total dividend for year 2010 would be HK30cents.

The excellent results were benefited from the strong growth of revenue, the enhancement of sales force, as well as the advantages of economic scales and improving cost control led by the full operation of the giant intermediate plant at Inner Mongolia. The overall gross profit margin increased by 0.4% to 39.5%. The price of the Group’s main product 6-APA went up by 11.7%. This led to the significant improvement of segmental profit margin that grew from 6.7% to 19.1%. The overseas market demand for intermediate products and bulk medicine grew significantly by 92.6% and accounted for 30.1% of total

sales. The sales of finished products were driven by brand loyalty effect, support from government policies and the increasing capability of the well-trained sales force. The finished products reported over 20% growth for another consecutive year.

Looking ahead, the Group will catalyze its process of internationalization in order to become a leading pharmaceutical company in the world. We will capitalize on our product vertical integration model, economies of scale and the TUL brand to seize the domestic and overseas opportunities proactively with a view to scoring another high. The Group believes that, with its solid foundation, the recognition and support of analysts and investors coupled with the vision and efforts from the management and all employees, we will continue to yield remarkable results.

Mr. Choy Kam Lok, Chairman of TUL concluded, “We started to step into a harvest period in 2010. The remarkable results reflect the Group’s capacity to be bigger and stronger. The Group will focus on the development of human insulin market, launch of highly profitable and competitive new products as well as expansion of sales in oversea markets. With our vision and strong ability, we will continue to launch new products and develop new markets and bring the greatest returns to our stakeholders.”

- End -

About The United Laboratories International Holdings Limited

Listed on the Stock Exchange of Hong Kong in June 2007, TUL is one of the leading pharmaceutical companies in China, principally engaged in the manufacturing and selling of medicines, and the bulk and intermediate products used to produce finished goods. As of 30 June 2010, the Group has a total of 177 products qualified to produce in the PRC and/or Hong Kong based on the Drug Registration Approvals in the PRC and Certificates of Drug or Product Registration in Hong Kong. 78 were in production, and 34 were listed in Insurance Catalogue. 12 finished products are in the list of the Nation’s Essential Drugs List. The group is currently a component of the Hang Seng Composite Index Series. For more information about TUL, please visit the company’s website at www.tul.com.hk.

Issued by Creativeline Communications for and on behalf of The United Laboratories International Holdings Limited. For further information, please contact:

Creativeline Communications

Mr. Wayne Chau / Ms. Sylvia Lau

Tel: (852) 2730 6212/ 6390 9406

Fax: (852) 2736 0745

Email : wayne@creativeline.com.hk / sylvia@creativeline.com.hk